Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Food Effect and CYP1A2 Induction Study in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02168205
Recruitment Status : Completed
First Posted : June 20, 2014
Last Update Posted : November 15, 2018
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:
This study will evaluate the effect of food and smoking on healthy older subjects taking pomalidomide.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Pomalidomide Other: Caffeine Other: Tobacco Phase 1

Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial.   More info ...

Detailed Description:

This study will be conducted in two parts. Parts 1 and 2 may be conducted in parallel and subjects are only allowed to participate in one part.

In Part 1, subjects will be randomly assigned to receive a single oral dose of 4 mg pomalidomide on Day 1 under fed (standard high fat breakfast) or fasted conditions. After a washout period of at least 3 and no more than 7 days, subjects will receive a single oral dose of 4 mg pomalidomide under the opposite condition to what they received in the first period.

In Part 2, healthy male smoker subjects must smoke approximately 20 cigarettes per day for a total of 10 days. Non-smokers will neither smoke nor be in the presence of smokers. All subjects will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, subjects will receive a single oral dose of 4 mg pomalidomide.

For both Parts 1 and 2, serial blood samples will be collected for determination of plasma pomalidomide concentrations.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Hase I Open-Label Two-Part Study To Evaluate The Effect Of Food and Of CYP1A2 Induction On Pomalidomide (CC-4047) Pharmacokinetics in Healthy Subjects
Actual Study Start Date : May 30, 2014
Actual Primary Completion Date : September 19, 2014
Actual Study Completion Date : September 19, 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 4 mg Pomalidomide - Fed
On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fed conditions.
Drug: Pomalidomide
Capsules

Experimental: 4 mg Pomalidomide - Fasted
On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fasted conditions
Drug: Pomalidomide
Capsules

Experimental: 4 mg Pomalidomide + caffeine - Non-smoking
Participants will remain in the clinical site for a total of 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
Drug: Pomalidomide
Capsules

Other: Caffeine
Capsules

Experimental: 4 mg Pomalidomide + caffeine - Smoking
Participants will be required to smoke approximately 20 cigarettes a day for 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
Drug: Pomalidomide
Capsules

Other: Caffeine
Capsules

Other: Tobacco
Cigarettes




Primary Outcome Measures :
  1. Pharmacokinetics - Cmax [ Time Frame: Up to 8 days for Part 1; up to 10 days for Part 2 ]
    Maximum observed concentration in plasma

  2. Pharmacokinetics - Tmax [ Time Frame: Up to 8 days for Part 1; up to 10 days for Part 2 ]
    Time to maximum observed concentration in plasma

  3. Pharmacokinetics - AUC [ Time Frame: Up to 8 days for Part 1; up to 10 days for Part 2 ]
    Area under the plasma concentration-time curve

  4. Pharmacokinetics - T1/2 [ Time Frame: Up to 8 days for Part 1; up to 10 days for Part 2 ]
    Terminal half-life

  5. Pharmacokinetics - Vz/f [ Time Frame: Up to 8 days for Part 1; up to 10 days for Part 2 ]
    Apparent volume of distribution

  6. Pharmacokinetics - CL/F [ Time Frame: Up to 8 days for Part 1; up to 10 days for Part 2 ]
    Apparent total body clearance


Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Approximately 1 month ]
    Number of participants with adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Part 1: 1.Must understand and voluntarily sign a written Informed Consent prior to any study-related procedures being performed.

    2.Must be able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.

    3.Must be male or postmenopausal* women of any race between ≥61 to ≤85 years of age (inclusive) at the time of signing the Informed Consent, and in good health as determined by a physical exam, clinical laboratory safety test results, vital signs, and 12 lead Electrocardiogram.

    * =Naturally postmenopausal for at least 24 consecutive months (ie, who has not had menses at any time in the preceding 24 consecutive months) 4.Subjects must be a non smoker. 5.Clinical laboratory tests must be within normal limits or acceptable to the Principal Investigator (PI).

    6.Must have a normal or clinically acceptable 12-lead Electrocardiogram. 7.Must be afebrile (febrile is defined as ≥ 38.0ºC or 100.4 Fahrenheit), with supine systolic blood pressure (BP): 90 to 150 mmHg, supine diastolic blood pressure: 60 to 95 mmHg, and pulse rate: 40 to 110 bpm and controlled on medications if they are indicated (especially for blood pressure).

    1. If a subject has a diagnosis of hypertension, the range for BP and pulse rate will be the one that is considered well controlled on medication.

      8.Must practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female that can get pregnant while participating in the study, during dose interruptions and for at least 28 days following study drug discontinuation, even if he has undergone a successful vasectomy.

      * = True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Period abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of contraception 9.Must agree to refrain from donating sperm or semen while participating in this study and for at least 28 days following the last dose of study drug.

      10.Must agree to refrain from donating blood or plasma (other than for this study) while participating in this study and for at least 28 days following the last dose of study drug.

      11.Must agree to comply with the conditions described in the counseling document (part of the pomalidomide Pregnancy Prevention Risk Management Plan.

      Part 2

      1. Must understand and voluntarily sign a written informed consent prior to any study-related procedures being performed.
      2. Must be able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.
      3. Must be male of any race between 40 to 80 years of age (inclusive) at the time of signing the Informed Consent, and in good health as determined by a physical exam, clinical laboratory safety test results, vital signs, and 12 lead electrocardiogram.
      4. Cohort A subjects (smokers) must have a history of smoking for >5 years and currently smoke ≥1 pack (20-25) cigarettes per day; and urine cotinine level at screening and baseline (Day -1) indicate subject is heavy smoker.
      5. Cohort B subjects (non-smokers) must have not smoked for >5 years (Cohort B).
      6. Clinical laboratory tests must be within normal limits or acceptable to the Principal Investigator.
      7. Must have a normal or clinically acceptable 12-lead Electrocardiogram, with a QTcF value ≤ 450 msec.
      8. Must be afebrile (febrile is defined as ≥ 38.0ºC or 100.4 Fahrenheit), with supine systolic blood pressure (BP): 90 to 150 mmHg, supine diastolic blood pressure: 60 to 95 mmHg, and pulse rate: 40 to 110 bpm and controlled on medications if they are indicated (especially for blood pressure).
      9. Must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female that can get pregnant while participating in the study, during dose interruptions and for at least 28 days following study drug discontinuation, even if he has undergone a successful vasectomy.
      10. Must agree to refrain from donating sperm or semen while participating in this study and for at least 28 days following the last dose of study drug.
      11. Must agree to refrain from donating blood or plasma (other than for this study) while participating in this study and for at least 28 days following the last dose of study drug.
      12. Must agree to comply with the conditions described in the counseling document (part of the pomalidomide Pregnancy Prevention Risk Management Plan.

      Exclusion Criteria:

  • Both Parts:

    1. History of any clinically significant and relevant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, known hypersensitivity to a member of the class of drugs that can modulate the immune system, or other major disorders.

      1. Subjects with well-controlled hypertension, hyperlipidemia, gout, asthma/chronic obstructive pulmonary disease, hypothyroidism and other common age-related disorders, requiring treatment and being well-controlled on concomitant prescription medication(s) will be eligible for inclusion in the study.
      2. Subjects with diabetes, significant gastrointestinal diseases or hematologic disorders should not be included in the study.
    2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.
    3. Used any prescribed systemic or topical medication within 30 days of the first dose administration, unless these medications are chronically administered and Sponsor agreement is obtained.
    4. Used any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration, unless these medications are chronically administered and Sponsor agreement is obtained.
    5. Has any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism and excretion, e.g., bariatric procedure.
    6. Donated blood or plasma within 8 weeks before the first dose administration to a blood bank or blood donation center.
    7. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual within 2 years before dosing, or positive drug screening test reflecting consumption of illicit drugs.
    8. History of alcohol abuse (as defined by the current version of the DSM) within 2 years before dosing, or positive alcohol screen.
    9. Known to have serum hepatitis or known to be a carrier of the hepatitis B surface antigen, or hepatitis C antibody, or have a positive result to the test for Human Immunodeficiency Virus antibodies at Screening.
    10. Exposed to an investigational drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer).
    11. Received vaccination (excluding seasonal flu vaccination) within 90 days of the study drug administration.
    12. Subjects who are part of the staff personnel or family members of the investigational study staff.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02168205


Locations
Layout table for location information
United States, Florida
Covance Clinical Research Unit
Daytona Beach, Florida, United States, 32117
Sponsors and Collaborators
Celgene
Investigators
Layout table for investigator information
Study Director: Edward O'Mara, MD Celgene
Additional Information:
Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT02168205    
Other Study ID Numbers: CC-4047-CP-011
First Posted: June 20, 2014    Key Record Dates
Last Update Posted: November 15, 2018
Last Verified: November 2018
Keywords provided by Celgene:
Healthy volunteer
Pharmacokinetics
Pomalyst
Pomalidomide
Food effect
smoker
Additional relevant MeSH terms:
Layout table for MeSH terms
Pomalidomide
Caffeine
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Immunologic Factors
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents